Tapi Nl Bv, based in Israel, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is RIBOCICLIB SUCCINATE, with a corresponding US DMF Number 35288.
Remarkably, this DMF maintains an Active status since its submission on November 26, 2020, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of January 22, 2021, and payment made on October 09, 2020, indicating their dedication to facilitating drug approvals, Categorized as Type II